AU2009303335B2 - Activators of human pyruvate kinase - Google Patents

Activators of human pyruvate kinase Download PDF

Info

Publication number
AU2009303335B2
AU2009303335B2 AU2009303335A AU2009303335A AU2009303335B2 AU 2009303335 B2 AU2009303335 B2 AU 2009303335B2 AU 2009303335 A AU2009303335 A AU 2009303335A AU 2009303335 A AU2009303335 A AU 2009303335A AU 2009303335 B2 AU2009303335 B2 AU 2009303335B2
Authority
AU
Australia
Prior art keywords
benzo
dihydro
dioxinyl
difluorophenyl
cio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009303335A
Other languages
English (en)
Other versions
AU2009303335A1 (en
Inventor
Douglas S. Auld
Matthew Boxer
James Inglese
Jian-kang JIANG
Amanda P. Skoumbourdis
Craig J. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2009303335A1 publication Critical patent/AU2009303335A1/en
Application granted granted Critical
Publication of AU2009303335B2 publication Critical patent/AU2009303335B2/en
Priority to AU2016216705A priority Critical patent/AU2016216705B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2009303335A 2008-10-09 2009-10-09 Activators of human pyruvate kinase Active AU2009303335B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016216705A AU2016216705B2 (en) 2008-10-09 2016-08-19 Activators of human pyruvate kinase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10409108P 2008-10-09 2008-10-09
US61/104,091 2008-10-09
PCT/US2009/060237 WO2010042867A2 (en) 2008-10-09 2009-10-09 Activators of human pyruvate kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016216705A Division AU2016216705B2 (en) 2008-10-09 2016-08-19 Activators of human pyruvate kinase

Publications (2)

Publication Number Publication Date
AU2009303335A1 AU2009303335A1 (en) 2010-04-15
AU2009303335B2 true AU2009303335B2 (en) 2016-05-19

Family

ID=41462200

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009303335A Active AU2009303335B2 (en) 2008-10-09 2009-10-09 Activators of human pyruvate kinase
AU2016216705A Active AU2016216705B2 (en) 2008-10-09 2016-08-19 Activators of human pyruvate kinase

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016216705A Active AU2016216705B2 (en) 2008-10-09 2016-08-19 Activators of human pyruvate kinase

Country Status (7)

Country Link
US (4) US8841305B2 (enExample)
EP (2) EP3173415B1 (enExample)
JP (2) JP5632379B2 (enExample)
AU (2) AU2009303335B2 (enExample)
CA (2) CA2740148C (enExample)
ES (1) ES2620634T3 (enExample)
WO (1) WO2010042867A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019139A2 (en) 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
JP5632379B2 (ja) 2008-10-09 2014-11-26 アメリカ合衆国 ヒトピルビン酸キナーゼ活性化剤
EP2417123A2 (en) 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
DK2427441T3 (en) 2009-05-04 2017-03-20 Agios Pharmaceuticals Inc PKM2 Activators for use in the treatment of cancer
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CR20170071A (es) 2009-06-29 2017-03-28 Agios Pharmaceuticals Inc Compuestos terapeuticos y composiciones
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
CA2797694A1 (en) * 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
EP2632920A1 (en) 2010-10-27 2013-09-04 Dynamix Pharmaceuticals Ltd. Sulfonamides for the modulation of pkm2
EP2651898B1 (en) 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
WO2012088314A1 (en) * 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
ME03074B (me) 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Akтivatori piruvat kinaze za upotrebu u terapiji
WO2012151440A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
EP3372230B1 (en) 2011-05-03 2020-08-12 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
WO2013005157A1 (en) * 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
WO2013027168A1 (en) * 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
DE102012207707A1 (de) * 2012-05-09 2013-11-28 Deutsches Zentrum für Luft- und Raumfahrt e.V. Minimalinvasives Instrument für die robotische Chirurgie
WO2014062838A2 (en) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
WO2014074848A1 (en) * 2012-11-08 2014-05-15 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions and their use as pkm2 modulators
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN104370936A (zh) * 2014-09-28 2015-02-25 苏州维泰生物技术有限公司 一种新型丙酮酸激酶m2激活剂及其合成方法
MA44392B1 (fr) 2015-06-11 2023-10-31 Agios Pharmaceuticals Inc Procédés d'utilisation d'activateurs de la pyruvate kinase
KR101713678B1 (ko) * 2015-08-24 2017-03-09 대우제약 주식회사 신규 화합물 4-Ethyl-7-(2-fluoro-benzylsulfanyl)-2-methyl-1-thia-3b, 5, 6-triaza-cyclopenta[a]indene 및 이를 포함하는 항암제용 약제학적 조성물
JP7332295B2 (ja) 2016-01-25 2023-08-23 スーパ－メタリクス，インコーポレイテッド． 四ホウ化タングステンの結合材組成物及びそれらの研磨方法
PT3448859T (pt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
SG11202001262QA (en) 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in treating blood disorders
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
US12233063B2 (en) 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) * 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
SG11202108744WA (en) * 2019-02-13 2021-09-29 Agios Pharmaceuticals Inc Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
CN110483504B (zh) * 2019-08-02 2022-04-26 桂林理工大学 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
CN114615977B (zh) 2019-09-19 2025-01-14 诺沃挪第克健康护理股份公司 丙酮酸激酶r(pkr)活化组合物
DE102019129527A1 (de) 2019-10-31 2021-05-06 Forschungszentrum Jülich GmbH Inhibitoren für Bromodomänen
US20230062100A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105117A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US12337005B2 (en) 2020-05-26 2025-06-24 University Of Iowa Research Foundation Methods of treating thrombosis
EP4185293A4 (en) * 2020-07-21 2025-01-15 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CA3231728A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
CN118434720A (zh) * 2021-12-22 2024-08-02 西特瑞治疗有限公司 作为丙酮酸激酶调节剂的酞嗪衍生物
CN115010721B (zh) * 2022-03-14 2023-06-13 五邑大学 一种荧光探针及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593102A (en) * 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
WO1993013072A1 (en) * 1991-12-20 1993-07-08 Italfarmaco S.P.A. 5-isoquinolinesulfonamide derivatives as protein kinase inhibiting agents
WO2002095063A1 (en) * 2001-05-23 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pyruvate-kinase as a novel target molecule
WO2003106381A2 (en) * 2002-06-12 2003-12-24 Exelixis, Inc. Human adam-10 inhibitors
US20070032418A1 (en) * 2003-02-25 2007-02-08 Ambion, Inc Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998828A (en) * 1975-01-31 1976-12-21 Pfizer Inc. 4-[2-(1,3-Dialkyl-1,2,3,4-tetra-hydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidine sulfonamide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2948434A1 (de) * 1979-12-01 1981-06-11 Hoechst Ag, 6000 Frankfurt 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
JPH0667926B2 (ja) * 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0804428B1 (en) 1995-01-20 2007-12-26 G.D. Searle LLC. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
SK11422001A3 (sk) * 1999-02-09 2002-04-04 3-Dimensional Pharmaceuticals Inc. Heteroarylamidíny, metylamidíny a guanidíny ako inhibítory proteázy
US6211182B1 (en) 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
IT1313592B1 (it) * 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
AR032885A1 (es) * 2000-08-16 2003-12-03 Actelion Pharmaceuticals Ltd Bis-sulfonamidas, composiciones farmaceuticas, procedimiento para prepararlas y el uso de las mismas para la produccion de las composiciones farmaceuticas
ATE380818T1 (de) * 2002-03-28 2007-12-15 Lilly Co Eli Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
AU2003266272A1 (en) * 2002-08-12 2004-03-03 Amynon Bio Tech Gmbh Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)
US7754884B2 (en) * 2005-01-03 2010-07-13 Vanderbilt University Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
WO2005074946A1 (en) * 2004-02-10 2005-08-18 Adenobio N.V. Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases
EP1720874A4 (en) * 2004-02-24 2010-03-03 Bioaxone Therapeutique Inc 4-SUBSTITUTED PIPERIDINE DERIVATIVES
CA2577309C (en) * 2004-06-24 2013-10-22 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
TW200606152A (en) 2004-07-02 2006-02-16 Tanabe Seiyaku Co Piperidine compound and process for preparing the same
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
WO2006055880A2 (en) * 2004-11-16 2006-05-26 Genzyme Corporation Diagnostic pkm2 methods and compositions
EP1853586B1 (en) * 2005-02-18 2013-07-24 AstraZeneca AB Antibacterial piperidine derivatives
AU2006331963A1 (en) * 2005-12-22 2007-07-05 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
JP2009521490A (ja) * 2005-12-22 2009-06-04 スミスクライン ビーチャム コーポレーション 化合物
EA200801551A1 (ru) * 2006-01-20 2009-02-27 Смитклайн Бичем Корпорейшн Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
WO2008019139A2 (en) * 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
CL2007003223A1 (es) * 2006-11-10 2008-01-11 Wyeth Corp Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
CA2680139A1 (en) * 2007-03-05 2008-09-12 Biolipox Ab New methylenebisphenyl compounds useful in the treatment of inflammation
US7897776B2 (en) * 2007-04-23 2011-03-01 Salutria Pharmaceuticals Llc Sulfonamide containing compounds for treatment of inflammatory disorders
WO2009025781A1 (en) * 2007-08-16 2009-02-26 Beth Israel Deaconess Medical Center Activators of pyruvate kinase m2 and methods of treating disease
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5632379B2 (ja) 2008-10-09 2014-11-26 アメリカ合衆国 ヒトピルビン酸キナーゼ活性化剤
EP2575815A4 (en) * 2010-06-04 2013-12-25 Albany Molecular Res Inc GLYCIN TRANSPORTER 1 INHIBITORS, METHODS OF MAKING THE SAME, AND USES THEREOF

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593102A (en) * 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
WO1993013072A1 (en) * 1991-12-20 1993-07-08 Italfarmaco S.P.A. 5-isoquinolinesulfonamide derivatives as protein kinase inhibiting agents
WO2002095063A1 (en) * 2001-05-23 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pyruvate-kinase as a novel target molecule
WO2003106381A2 (en) * 2002-06-12 2003-12-24 Exelixis, Inc. Human adam-10 inhibitors
US20070032418A1 (en) * 2003-02-25 2007-02-08 Ambion, Inc Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same

Also Published As

Publication number Publication date
US20150105395A1 (en) 2015-04-16
AU2009303335A1 (en) 2010-04-15
JP2015078188A (ja) 2015-04-23
JP5632379B2 (ja) 2014-11-26
WO2010042867A2 (en) 2010-04-15
US20160199370A1 (en) 2016-07-14
EP3173415A3 (en) 2017-08-23
JP5960770B2 (ja) 2016-08-02
US8937067B2 (en) 2015-01-20
JP2012505247A (ja) 2012-03-01
US9707230B2 (en) 2017-07-18
WO2010042867A3 (en) 2010-08-05
US20110195958A1 (en) 2011-08-11
EP2344453B1 (en) 2016-12-28
ES2620634T3 (es) 2017-06-29
US9290512B2 (en) 2016-03-22
AU2016216705B2 (en) 2018-04-26
US20120245141A1 (en) 2012-09-27
EP3173415B1 (en) 2019-06-05
CA3041868A1 (en) 2010-04-15
AU2016216705A1 (en) 2016-09-08
EP3173415A2 (en) 2017-05-31
US8841305B2 (en) 2014-09-23
CA2740148C (en) 2019-06-18
CA2740148A1 (en) 2010-04-15
EP2344453A2 (en) 2011-07-20
CA3041868C (en) 2023-03-07

Similar Documents

Publication Publication Date Title
AU2009303335B2 (en) Activators of human pyruvate kinase
AU2018202568B2 (en) Heterocyclyl compounds as MEK inhibitors
AU2011245441B2 (en) Activators of human pyruvate kinase
CA3069720A1 (en) Carboxamides as modulators of sodium channels
WO1998054153A1 (en) Novel cyclic diamine compounds and medicine containing the same
KR20100120709A (ko) Ｐｉｍ 키나제 억제제 및 이들의 사용 방법
SG176042A1 (en) 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
KR20120093428A (ko) 스핑고신 키나아제 저해제
CA2956745C (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
EP1723126A2 (en) Novel mch receptor antagonists
US6969711B2 (en) Cyclic diamine compounds and medicine containing the same
KR20190022728A (ko) 증식 장애의 치료를 위한 미토콘드리아 억제제
WO2023146513A1 (en) Compounds and methods of use thereof
WO2007025776A2 (en) Cysteine protease inhibitors
AU2015201398A1 (en) Activators of human pyruvate kinase
OA17133A (en) Heterocyclyl compounds as MEK inhibitors
NZ710293B2 (en) Amides as modulators of sodium channels
OA17318A (en) Heterocyclyl Compounds.
NZ710293A (en) Amides as modulators of sodium channels

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)